 |
humanized monoclonal antibody that blocks activity of complement component C5 |
|---|---|
| Trade Name | |
| Orphan Indication | Hemoglobinuria |
| USA Market Approval | USA |
| USA Designation Date | 2017-01-04 00:00:00 |
| Sponsor | Alexion Pharmaceuticals, Inc.;55 Cambridge Parkway, Suite 800;Cambridge, Massachusetts, 02142 |
